|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sjodahl G, Lauss M, Lovgren K, Chebil G,
Gudjonsson S, Veerla S, Patschan O, Aine M, Fernö M, Ringnér M, et
al: A molecular taxonomy for urothelial carcinoma. Clin Cancer Res.
18:3377–3386. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
European Association of Urology (EAU), .
EAU Guidelines on Urological Infections. EAU Guidelines Office;
Arnhem: 2018, simplehttps://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Urological-Infections-2018-large-text.pdf
|
|
5
|
Czerniak B, Dinney C and McConkey D:
Origins of bladder cancer. Annu Rev Pathol. 11:149–174. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gruber K: Coffee consumption and bladder
cancer are linked, analysis shows. BMJ. 350:h14772015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Markowski MC, Boorjian SA, Burton JP, Hahn
NM, Ingersoll MA, Maleki Vareki S, Pal SK and Sfanos KS: The
microbiome and genitourinary cancer: A collaborative review. Eur
Urol. 75:637–646. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Knowles MA and Hurst CD: Molecular biology
of bladder cancer: New insights into pathogenesis and clinical
diversity. Nat Rev Cancer. 15:25–41. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang Q, Su M, Lu G and Wang J: The
complexity of bladder cancer: Long noncoding RNAs are on the stage.
Mol Cancer. 12:1012013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen M, Li J, Zhuang C and Cai Z:
Increased lncRNA ABHD11-AS1 represses the malignant phenotypes of
bladder cancer. Oncotarget. 8:28176–28186. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen M, Zhuang C, Liu Y, Li J, Dai F, Xia
M, Zhan Y, Lin J, Chen Z, He A, et al: Tetracycline-inducible shRNA
targeting antisense long non-coding RNA HIF1A-AS2 represses the
malignant phenotypes of bladder cancer. Cancer Lett. 376:155–164.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lopez-Beltran A, Henriques V, Montironi R,
Cimadamore A, Raspollini MR and Cheng L: Variants and new entities
of bladder cancer. Histopathology. 74:77–96. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Boormans JL, Zwarthoff EC, Black PC,
Goebell PJ, Kamat AM, Nawroth R, Seiler R, Williams SB and
Schmitz-Dräger BJ: New horizons in bladder cancer research. Urol
Oncol. March 7–2019.(Epub ahead of print). View Article : Google Scholar
|
|
14
|
Kim S, Kim Y, Kong J, Kim E, Choi JH, Yuk
HD, Lee H, Kim HR, Lee KH, Kang M, et al: Epigenetic regulation of
mammalian Hedgehog signaling to the stroma determines the molecular
subtype of bladder cancer. Elife. 8:e430242019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen LM, Chang M, Dai Y, Chai KX, Dyrskjøt
L, Sanchez-Carbayo M, Szarvas T, Zwarthoff EC, Lokeshwar V,
Jeronimo C, et al: External validation of a multiplex urinary
protein panel for the detection of bladder cancer in a multicenter
cohort. Cancer Epidemiol Biomarkers Prev. 23:1804–1812. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Loras A, Suarez-Cabrera C, Martinez-Bisbal
MC, Quintás G, Paramio JM, Martínez-Máñez R, Gil S and Ruiz-Cerdá
JL: Integrative metabolomic and transcriptomic analysis for the
study of bladder cancer. Cancers (Basel). 11:6862019. View Article : Google Scholar
|
|
17
|
Sjodahl G, Jackson CL, Bartlett JM,
Siemens DR and Berman DM: Molecular profiling in muscle-invasive
bladder cancer: More than the sum of its parts. J Pathol.
247:563–573. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Damrauer JS, Hoadley KA, Chism DD, Fan C,
Tiganelli CJ, Wobker SE, Yeh JJ, Milowsky MI, Iyer G, Parker JS and
Kim WY: Intrinsic subtypes of high-grade bladder cancer reflect the
hallmarks of breast cancer biology. Proc Natl Acad Sci USA.
111:3110–3115. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Choi W, Porten S, Kim S, Willis D, Plimack
ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, et al:
Identification of distinct basal and luminal subtypes of
muscle-invasive bladder cancer with different sensitivities to
frontline chemotherapy. Cancer Cell. 25:152–165. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Robertson AG, Kim J, Al-Ahmadie H,
Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA,
Akbani R, et al: Comprehensive molecular characterization of
muscle-invasive bladder cancer. Cell. 174:10332018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Davis NF, Brady CM and Creagh T:
Interstitial cystitis/painful bladder syndrome: Epidemiology,
pathophysiology and evidence-based treatment options. Eur J Obstet
Gynecol Reprod Biol. 175:30–37. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fall M, Baranowski AP, Elneil S, Engeler
D, Hughes J, Messelink EJ, Oberpenning F and de C Williams AC;
European Association of Urology, : EAU guidelines on chronic pelvic
pain. Eur Urol. 57:35–48. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hanno P, Lin A, Nordling J, van Ophoven A,
Ueda T and Wein A; Bladder Pain Syndrome Committee of the
International Consultation on Incontinence, : Bladder pain syndrome
committee of the international consultation on incontinence.
Neurourol Urodyn. 29:191–198. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Clemens JQ, Mullins C, Ackerman AL,
Bavendam T, van Bokhoven A, Ellingson BM, Harte SE, Kutch JJ, Lai
HH, Martucci KT, et al: Urologic chronic pelvic pain syndrome:
Insights from the MAPP research network. Nat Rev Urol. 16:187–200.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
van de Merwe JP, Nordling J, Bouchelouche
P, Bouchelouche K, Cervigni M, Daha LK, Elneil S, Fall M,
Hohlbrugger G, Irwin P, et al: Diagnostic criteria, classification,
and nomenclature for painful bladder syndrome/interstitial
cystitis: An ESSIC proposal. Eur Urol. 53:60–67. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hanno PM, Burks DA, Clemens JQ, Dmochowski
RR, Erickson D, Fitzgerald MP, Forrest JB, Gordon B, Gray M, Mayer
RD, et al: AUA guideline for the diagnosis and treatment of
interstitial cystitis/bladder pain syndrome. J Urol. 185:2162–2170.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Akiyama Y, Maeda D, Katoh H, Morikawa T,
Niimi A, Nomiya A, Sato Y, Kawai T, Goto A, Fujimura T, et al:
Molecular taxonomy of interstitial cystitis/bladder pain syndrome
based on whole transcriptome profiling by next-generation RNA
sequencing of bladder mucosal biopsies. J Urol. 202:290–300. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Peters KM, Killinger KA, Mounayer MH and
Boura JA: Are ulcerative and nonulcerative interstitial
cystitis/painful bladder syndrome 2 distinct diseases? A study of
coexisting conditions. Urology. 78:301–308. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Seyhan AA and Carini C: Are innovation and
new technologies in precision medicine paving a new era in patients
centric care? J Transl Med. 17:1142019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Clish CB: Metabolomics: An emerging but
powerful tool for precision medicine. Cold Spring Harb Mol Case
Stud. 1:a0005882015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kuehnbaum NL and Britz-McKibbin P: New
advances in separation science for metabolomics: Resolving chemical
diversity in a post-genomic era. Chem Rev. 113:2437–2468. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Griffin JL and Shockcor JP: Metabolic
profiles of cancer cells. Nat Rev Cancer. 4:551–561. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vander Heiden MG: Targeting cancer
metabolism: A therapeutic window opens. Nat Rev Drug Discov.
10:671–684. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pereira MM, Shori DK, Dormer RL and
McPherson MA: Studies on phosphorylation of calcineurin. Biochem
Soc Trans. 18:4471990. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gatenby RA and Gillies RJ: Why do cancers
have high aerobic glycolysis? Nat Rev Cancer. 4:891–899. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Han X: Lipidomics for studying metabolism.
Nat Rev Endocrinol. 12:668–679. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lydic TA and Goo YH: Lipidomics unveils
the complexity of the lipidome in metabolic diseases. Clin Transl
Med. 7:42018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Blanksby SJ and Mitchell TW: Advances in
mass spectrometry for lipidomics. Annu Rev Anal Chem (Palo Alto
Calif). 3:433–465. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Emwas AH, Roy R, McKay RT, Tenori L,
Saccenti E, Gowda GAN, Raftery D, Alahmari F, Jaremko L, Jaremko M
and Wishart DS: NMR spectroscopy for metabolomics research.
Metabolites. 9:1232019. View Article : Google Scholar
|
|
41
|
Fiehn O and Kim J: Metabolomics insights
into pathophysiological mechanisms of interstitial cystitis. Int
Neurourol J. 18:106–114. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen Z and Kim J: Urinary proteomics and
metabolomics studies to monitor bladder health and urological
diseases. BMC Urol. 16:112016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhu CZ, Ting HN, Ng KH and Ong TA: A
review on the accuracy of bladder cancer detection methods. J
Cancer. 10:4038–4044. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kim J, Kim WT and Kim WJ: Advances in
urinary biomarker discovery in urological research. Investig Clin
Urol. 61 (Suppl 1):S8–S22. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nicholson JK, Connelly J, Lindon JC and
Holmes E: Metabonomics: A platform for studying drug toxicity and
gene function. Nat Rev Drug Discov. 1:153–161. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sreekumar A, Poisson LM, Rajendiran TM,
Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, et al:
Metabolomic profiles delineate potential role for sarcosine in
prostate cancer progression. Nature. 457:910–914. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jobard E, Pontoizeau C, Blaise BJ,
Bachelot T, Elena-Herrmann B and Tredan O: A serum nuclear magnetic
resonance-based metabolomic signature of advanced metastatic human
breast cancer. Cancer Lett. 343:33–41. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Carrola J, Rocha CM, Barros AS, Gil AM,
Goodfellow BJ, Carreira IM, Bernardo J, Gomes A, Sousa V, Carvalho
L and Duarte IF: Metabolic signatures of lung cancer in biofluids:
NMR-based metabonomics of urine. J Proteome Res. 10:221–230. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen F, Xue J, Zhou L, Wu S and Chen Z:
Identification of serum biomarkers of hepatocarcinoma through
liquid chromatography/mass spectrometry-based metabonomic method.
Anal Bioanal Chem. 401:1899–1904. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Rodrigues D, Jeronimo C, Henrique R, Belo
L, de Lourdes Bastos M, de Pinho PG and Carvalho M: Biomarkers in
bladder cancer: A metabolomic approach using in vitro and ex vivo
model systems. Int J Cancer. 139:256–268. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sahu D, Lotan Y, Wittmann B, Neri B and
Hansel DE: Metabolomics analysis reveals distinct profiles of
nonmuscle-invasive and muscle-invasive bladder cancer. Cancer Med.
6:2106–2120. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Yumba Mpanga A, Siluk D, Jacyna J, Szerkus
O, Wawrzyniak R, Markuszewski M, Matuszewski M, Kaliszan R and
Markuszewski MJ: Targeted metabolomics in bladder cancer: From
analytical methods development and validation towards application
to clinical samples. Anal Chim Acta. 1037:188–199. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Jin X, Yun SJ, Jeong P, Kim IY, Kim WJ and
Park S: Diagnosis of bladder cancer and prediction of survival by
urinary metabolomics. Oncotarget. 5:1635–1645. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yang K and Han X: Lipidomics: Techniques,
applications, and outcomes related to biomedical sciences. Trends
Biochem Sci. 41:954–969. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ellis DI, Dunn WB, Griffin JL, Allwood JW
and Goodacre R: Metabolic fingerprinting as a diagnostic tool.
Pharmacogenomics. 8:1243–1266. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wang C, Wang M and Han X: Applications of
mass spectrometry for cellular lipid analysis. Mol Biosyst.
11:698–713. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Dill AL, Eberlin LS, Costa AB, Zheng C,
Ifa DR, Cheng L, Masterson TA, Koch MO, Vitek O and Cooks RG:
Multivariate statistical identification of human bladder carcinomas
using ambient ionization imaging mass spectrometry. Chemistry.
17:2897–2902. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Lee MY, Yeon A, Shahid M, Cho E, Sairam V,
Figlin R, Kim KH and Kim J: Reprogrammed lipid metabolism in
bladder cancer with cisplatin resistance. Oncotarget.
9:13231–13243. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Kind T, Cho E, Park TD, Deng N, Liu Z, Lee
T, Fiehn O and Kim J: Interstitial cystitis-associated urinary
metabolites identified by mass-spectrometry based metabolomics
analysis. Sci Rep. 6:392272016. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Clemens JQ, Mullins C, Kusek JW, Kirkali
Z, Mayer EA, Rodríguez LV, Klumpp DJ, Schaeffer AJ, Kreder KJ,
Buchwald D, et al: The MAPP research network: A novel study of
urologic chronic pelvic pain syndromes. BMC Urol. 14:572014.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Parker KS, Crowley JR, Stephens-Shields
AJ, van Bokhoven A, Lucia MS, Lai HH, Andriole GL, Hooton TM,
Mullins C and Henderson JP: Urinary metabolomics identifies a
molecular correlate of interstitial cystitis/bladder pain syndrome
in a multidisciplinary approach to the study of chronic pelvic pain
(MAPP) research network cohort. EBioMedicine. 7:167–174. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Mbeutcha A, Lucca I, Mathieu R, Lotan Y
and Shariat SF: Current status of urinary biomarkers for detection
and surveillance of bladder cancer. Urol Clin North Am. 43:47–62.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zhang WT, Zhang ZW, Guo YD, Wang LS, Mao
SY, Zhang JF, Liu MN and Yao XD: Discovering biomarkers in bladder
cancer by metabolomics. Biomark Med. 12:1347–1359. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kuo HC: Potential urine and serum
biomarkers for patients with bladder pain syndrome/interstitial
cystitis. Int J Urol. 21 (Suppl 1):S34–S41. 2014. View Article : Google Scholar
|
|
65
|
Srivastava S, Roy R, Singh S, Kumar P,
Dalela D, Sankhwar SN, Goel A and Sonkar AA: Taurine-a possible
fingerprint biomarker in non-muscle invasive bladder cancer: A
pilot study by 1H NMR spectroscopy. Cancer Biomark. 6:11–20. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Anderson NM, Mucka P, Kern JG and Feng H:
The emerging role and targetability of the TCA cycle in cancer
metabolism. Protein Cell. 9:216–237. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Pasikanti KK, Esuvaranathan K, Ho PC,
Mahendran R, Kamaraj R, Wu QH, Chiong E and Chan EC: Noninvasive
urinary metabonomic diagnosis of human bladder cancer. J Proteome
Res. 9:2988–2995. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Wittmann BM, Stirdivant SM, Mitchell MW,
Wulff JE, McDunn JE, Li Z, Dennis-Barrie A, Neri BP, Milburn MV,
Lotan Y and Wolfert RL: Bladder cancer biomarker discovery using
global metabolomic profiling of urine. PLoS One. 9:e1158702014.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Shen C, Sun Z, Chen D, Su X, Jiang J, Li
G, Lin B and Yan J: Developing urinary metabolomic signatures as
early bladder cancer diagnostic markers. OMICS. 19:1–11. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Pasikanti KK, Esuvaranathan K, Hong Y, Ho
PC, Mahendran R, Raman Nee Mani L, Chiong E and Chan EC: Urinary
metabotyping of bladder cancer using two-dimensional gas
chromatography time-of-flight mass spectrometry. J Proteome Res.
12:3865–3873. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Putluri N, Shojaie A, Vasu VT, Vareed SK,
Nalluri S, Putluri V, Thangjam GS, Panzitt K, Tallman CT, Butler C,
et al: Metabolomic profiling reveals potential markers and
bioprocesses altered in bladder cancer progression. Cancer Res.
71:7376–7386. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Tripathi P, Somashekar BS, Ponnusamy M,
Gursky A, Dailey S, Kunju P, Lee CT, Chinnaiyan AM, Rajendiran TM
and Ramamoorthy A: HR-MAS NMR tissue metabolomic signatures
cross-validated by mass spectrometry distinguish bladder cancer
from benign disease. J Proteome Res. 12:3519–3528. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Yang C, Sun X, Wang H, Lu T, Wu K, Guan Y,
Tang J, Liang J, Sun R, Guo Z, et al: Metabolomic profiling
identifies novel biomarkers and mechanisms in human bladder cancer
treated with submucosal injection of gemcitabine. Int J Mol Med.
44:1952–1962. 2019.PubMed/NCBI
|
|
74
|
Cao M, Zhao L, Chen H, Xue W and Lin D:
NMR-based metabolomic analysis of human bladder cancer. Anal Sci.
28:451–456. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Bansal N, Gupta A, Mitash N, Shakya PS,
Mandhani A, Mahdi AA, Sankhwar SN and Mandal SK: Low- and
high-grade bladder cancer determination via human serum-based
metabolomics approach. J Proteome Res. 12:5839–5850. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Wen H, Lee T, You S, Park SH, Song H,
Eilber KS, Anger JT, Freeman MR, Park S and Kim J: Urinary
metabolite profiling combined with computational analysis predicts
interstitial cystitis-associated candidate biomarkers. J Proteome
Res. 14:541–548. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Fukui Y, Kato M, Inoue Y, Matsubara A and
Itoh K: A metabonomic approach identifies human urinary
phenylacetylglutamine as a novel marker of interstitial cystitis. J
Chromatogr B Analyt Technol Biomed Life Sci. 877:3806–3812. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Lamale LM, Lutgendorf SK, Zimmerman MB and
Kreder KJ: Interleukin-6, histamine, and methylhistamine as
diagnostic markers for interstitial cystitis. Urology. 68:702–706.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Shahid M, Lee MY, Yeon A, Cho E, Sairam V,
Valdiviez L, You S and Kim J: Menthol, a unique urinary volatile
compound, is associated with chronic inflammation in interstitial
cystitis. Sci Rep. 8:108592018. View Article : Google Scholar : PubMed/NCBI
|
